In vivo molecular target assessment of matrix metalloproteinase inhibition (original) (raw)

References

  1. Ossowski, L., Clunie, G., Masucci, M.T. & Blasi, F. In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion. J. Cell Biol. 115, 1107–1112 (1991).
    Article CAS Google Scholar
  2. Chambers, A.F. & Matrisian, L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89, 1260–1270 (1997).
    Article CAS Google Scholar
  3. Frosch, B.A., Berquin, I., Emmert-Buck, M.R., Moin, K. & Sloane, B.F. Molecular regulation, membrane association and secretion of tumor cathepsin B. APMIS 107, 28–37 (1999).
    Article CAS Google Scholar
  4. Stearns, M.E. & Wang, M. Type IV collagenase (M(r) 72,000) expression in human prostate: Benign and malignant tissue. Cancer Res. 53, 878–883 (1993).
    CAS PubMed Google Scholar
  5. Davies, B. et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 53, 5365–5369 (1993).
    CAS PubMed Google Scholar
  6. Zucker, S. et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann. N.Y. Acad. Sci. 878, 212–227 (1999).
    Article CAS Google Scholar
  7. Moses, M.A. et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 58, 1395–1399 (1998).
    CAS PubMed Google Scholar
  8. Fang, J. et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. U.S.A. 97, 3884–3889 (2000).
    Article CAS Google Scholar
  9. Morgunova, E. et al. Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed. Science 284, 1667–1670 (1999).
    Article CAS Google Scholar
  10. Whittaker, M., Floyd, C.D., Brown, P. & Gearing, A. Design and therapeutic application of matrix metalloprotease inhibitors. Chem. Rev. 99, 2735–2776 (1999).
    Article CAS Google Scholar
  11. Shalinsky, D.R. et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. N.Y. Acad. Sci. 878, 236–270 (1999).
    Article CAS Google Scholar
  12. Brown, P. Clinical studies with matrix metalloproteinase inhibitors. APMIS 107, 174–180 (1999).
    Article CAS Google Scholar
  13. Nelson, A.R., Fingleton, B., Rothenberg, M.L. & Matrisian, L.M. Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol. 18, 1135–1149 (2000).
    Article CAS Google Scholar
  14. Koivunen, E. et al. Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnol. 17, 768–774 (1999).
    Article CAS Google Scholar
  15. Drummond, A.H. et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. N.Y. Acad. Sci. 878, 228–235 (1999).
    Article CAS Google Scholar
  16. Wojtowicz-Praga, S. et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 16, 2150–2156 (1998).
    Article CAS Google Scholar
  17. Erlichman, C. et al. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann. Oncol. 12, 389–395 (2001).
    Article CAS Google Scholar
  18. Zucker, S. Experimental models to identify antimetastatic drugs: Are we there yet? A position paper. Ann. N.Y. Acad. Sci. 878, 208–211 (1999).
    Article CAS Google Scholar
  19. Haq, M., Shafii, A., Zervos, E.E. & Rosemurgy, A.S. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res. 60, 3207–3211 (2000).
    CAS PubMed Google Scholar
  20. Van Noorden, C.J. et al. Ala-Pro-cresyl violet, a synthetic fluorogenic substrate for the analysis of kinetic parameters of dipeptidyl peptidase IV (CD26) in individual living rat hepatocytes. Anal. Biochem. 252, 71–77 (1997).
    Article CAS Google Scholar
  21. Van Noorden, C.J. et al. Heterogeneous suppression of experimentally induced colon cancer metastasis in rat liver lobes by inhibition of extracellular cathepsin B. Clin. Exp. Metastasis 16, 159–167 (1998).
    Article CAS Google Scholar
  22. Weissleder, R., Tung, C.H., Mahmood, U. & Bogdanov, A., Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nature Biotechnol. 17, 375–378 (1999).
    Article CAS Google Scholar
  23. Tung, C.H., Mahmood, U., Bredow, S. & Weissleder, R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res. 60, 4953–4958 (2000).
    CAS PubMed Google Scholar
  24. Marecos, E., Weissleder, R. & Bogdanov, A., Jr. Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model. Bioconjug. Chem. 9, 184–191 (1998).
    Article CAS Google Scholar
  25. Seltzer, J.L. et al. Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides. J. Biol. Chem. 265, 20409–20413 (1990).
    CAS PubMed Google Scholar
  26. Niedzwiecki, L., Teahan, J., Harrison, R.K. & Stein, R.L. Substrate specificity of the human matrix metalloproteinase stromelysin and the development of continuous fluorometric assays. Biochemistry 31, 12618–12623 (1992).
    Article CAS Google Scholar
  27. Giambernardi, T.A. et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol. 16, 483–496 (1998).
    Article CAS Google Scholar
  28. Knight, C.G., Willenbrock, F. & Murphy, G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 296, 263–266 (1992).
    Article CAS Google Scholar
  29. Callahan, R.J., Bogdanov, A., Jr., Fischman, A.J., Brady, T.J. & Weissleder, R. Preclinical evaluation and Phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging. Am. J. Roentgenol. 171, 137–143 (1998).
    Article CAS Google Scholar
  30. Chance, B. Near-infrared images using continuous, phase-modulated, and pulsed light with quantitation of blood and blood oxygenation. Ann. N.Y. Acad. Sci. 838, 29–45 (1998).
    Article CAS Google Scholar
  31. Mahmood, U., Tung, C.H., Bogdanov, A., Jr. & Weissleder, R. Near-infrared optical imaging of protease activity for tumor detection. Radiology 213, 866–870 (1999).
    Article CAS Google Scholar
  32. Ntziachristos, V., Yodh, A.G., Schnall, M. & Chance, B. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc. Natl. Acad. Sci. U.S.A. 97, 2767–2772 (2000).
    Article CAS Google Scholar
  33. Lozonschi, L. et al. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res. 59, 1252–1258 (1999).
    CAS PubMed Google Scholar
  34. Maekawa, R. et al. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 59, 1231–1235 (1999).
    CAS PubMed Google Scholar
  35. Ross, R. Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 340, 115–126 (1999).
    Article CAS Google Scholar
  36. Tsukifuji, R., Tagawa, K., Hatamochi, A. & Shinkai, H. Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis. Br. J. Cancer 80, 1087–1091 (1999).
    Article CAS Google Scholar
  37. Plantner, J.J., Jiang, C. & Smine, A. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. Exp. Eye Res. 67, 637–645 (1998).
    Article CAS Google Scholar
  38. Holskin, B.P. et al. A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. Anal. Biochem. 227, 148–155 (1995).
    Article CAS Google Scholar
  39. Ishiguro, N., Ito, T., Miyazaki, K. & Iwata, H. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. J. Rheumatol. 26, 34–40 (1999).
    CAS PubMed Google Scholar
  40. Giraudon, P., Buart, S., Bernard, A. & Belin, M.F. Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): Possible involvement in neurodegenerative processes. Mol. Psychiatry 2, 107–110, 184 (1997).
    Article CAS Google Scholar
  41. Tung, C.H., Bredow, S., Mahmood, U. & Weissleder, R. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjug. Chem. 10, 892–896 (1999).
    Article CAS Google Scholar
  42. Brown, P.D., Levy, A.T., Margulies, I.M., Liotta, L.A. & Stetler-Stevenson, W.G. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res. 50, 6184–6191 (1990).
    CAS PubMed Google Scholar
  43. Collier, I.E. et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J. Biol. Chem. 263, 6579–6587 (1988).
    CAS PubMed Google Scholar

Download references